i3 Genesis

Funding for early-stage
healthcare technologies
in development at Mount Sinai.

About i3 Genesis

i3 Genesis is an annual funding opportunity for early-stage healthcare technologies with clear potential for commercialization. Part of MSIP’s i3 Family of Funds, this opportunity aims to support and translate innovations by providing up to $50K to achieve value inflection points.

How it Works

Innovators seeking to develop their technology with the potential for commercialization can submit a proposal during the Request for Proposals (RFP) period. Submitted proposals are evaluated by a review panel of experts from the MSIP Business Development team in fields including digital health, medical devices, and therapeutics. Some will be selected to pitch their proposal to the review panel during a virtual session conducted via Zoom. Proposals will be judged and scored based on project novelty, feasibility, and market risks against the budget and milestones provided. Awardees will be selected based on recorded scores and recommendations from the review panel. Funding will be disbursed to awardees once the Principal Investigator and their Administrator sign an Informed Participation Letter (IPL). More details will be provided should you be selected for i3 Genesis funding.

The RFP period for 2023 is now closed. Please check back on this page for updates.

  • February 27
    i3 Genesis RFP period opens
  • March 27
    RFP submission due date
  • Late March to April
    Judging panel reviews submissions
  • May
    Presentations to judging panel and selection of awardees
  • June
    Awardees notified of selection
  • July:
    Project execution begins (pending the IPL signing and finalization of plans and budget)


Eligible applicants must:

  • have a well-defined technology or data gaps that could be addressed by applying for i3 Genesis funding.
  • be Mount Sinai faculty, staff, or a student with support of a faculty member or clinician. Multi-disciplinary teams are encouraged to apply.
  • request funding associated with milestone-based development plans (funding is not intended to support Principal or Senior Investigators’ salaries).

Proposals involving Human Subjects or Animal Research require extra steps, such as gaining formal approval from the Institutional Review Board (IRB) or Institutional Animal Care and Use Committee (IACUC).

How to Apply

The RFP period for 2023 is now closed. Please check back on this page for updates.

Contact Us

For more information, please reach out to Louise Lammers, PhD, Director of Business Development, Emerging Assets at louise.lammers@mssm.edu or William Chiang, PhD, Business Development Consultant, at william.chiang@mssm.edu.